Patients
Meeting the needs of patients by promoting the R&D of new radiopharmaceuticals and their industrialization.
ABOUT
2007
Year the Nancyclotep GIE was founded
3
Founding members united around a single platform
~30
Employees and some fifteen professions on site
1er
PET-Scan installed in a French university hospital, back in 2001
Our purpose
A platform designed to accelerate innovation
The aim of the Nancyclotep platform is to facilitate the use of innovative molecular imaging techniques in routine medical practice, thus meeting the needs of patients, the healthcare system, and industrial Research and Development (R&D), as well as academic research.
To date, the Economic Interest Group (GIE) comprises three members: the University Hospital of Nancy (CHRU), the University of Lorraine, and the company Posifit.
About thirty people work for Nancyclotep, bringing together a wide range of professions and expertise on the same site: radiochemists, radiopharmacists and industrial pharmacists, physicians, medical physicists, scientists, project managers, technicians, IT specialists, radiologic technologists, administrative assistants, and more.
GIE members
Three institutions, one shared ambition
A platform unique in France, bringing together on a single site every link in the molecular imaging chain, from research to the patient.
Since 1970
Our history
1970
1 / 11
-
1970
Creation of the Nuclear Medicine department at the new Brabois hospital (Prof. A. Bertrand)
-
2001
Installation of the first PET-Scan in a university hospital (CHRU) and the production cyclotron at the Brabois site
-
2007
Creation of the Nancyclotep economic interest group (GIE)
-
2008
Commissioning of the second PET-Scan at the CHRU (funded and operated by Nancyclotep)
-
2015
"FILODIM" project funded by the Lorraine Region enabling the acquisition of a PET-Scan
-
2018
Grant of €7.2M obtained through the European Regional Development Fund (FIGEDIM project) to make the CHRU of Nancy a reference site for clinical research and care in Nuclear Medicine and Targeted Internal Radiotherapy, with the support of the Regional Health Agency (ARS)
-
2019
Official launch of the RTIV project in the presence of the President of the French National Authority for Health
-
2020
Opening of the radiopharmaceutical production laboratory by Posifit
-
2022
Progressive commissioning of the R&D and production platform at the Brabois site
-
2023
Acquisition of an additional PET-Scan by Nancyclotep
-
2024
Design of the industrial project "PROTHERIUM"
Our roadmap
What we are working to move forward
Research
Promoting research in radiochemistry and radiopharmacy to develop the knowledge and methods driving progress in PET molecular imaging.
The pharmaceutical industry
Providing access to R&D, preclinical and clinical validation services, to reduce development costs and timelines.
Health authorities
Supporting health authorities in their search for reliable medical-economic information to define a coherent healthcare policy.
Quality approach
ISO 9001 certified
Nancyclotep is ISO 9001 certified for its Radiochemistry, Preclinical Research and Clinical Research activities. This certification reflects our commitment to quality, traceability and continuous improvement for the benefit of our partners and patients.
They support us
A project supported by the region’s public bodies
Since its creation, Nancyclotep has benefited from the support of public bodies investing in the scientific excellence of Nancy, the Grand Est Region and France. Beyond funding, this support reflects a shared ambition: making our region a recognized reference in molecular imaging and nuclear medicine.
Want to know more?
Clinical research, preclinical studies, radiochemistry, radiopharmacy: explore our activities or let’s talk about your project directly.